Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 2/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.41 |
| ▸ | HTR7 | P34969 | 3/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | GCGR | P47871 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.37 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17192217 | 0.84 | DRD2 (0.48) | DRD4DRD2DRD3SLC6A2SLC6A4 | |
| SCHEMBL15748133 | 0.82 | DRD2 (0.51) | DRD4DRD2DRD3SLC6A2SLC6A4 | |
| SCHEMBL15748140 | 0.81 | SIGMAR1 (0.53) | DRD2DRD3SLC6A4HTR7SIGMAR1 | |
| SCHEMBL17192218 | 0.77 | KCNH2 (0.58) | DRD4DRD2DRD3HTR7 | |
| SCHEMBL15748134 | 0.74 | SIGMAR1 (0.50) | DRD4DRD2DRD3HTR7CYP2A6 | |
| SCHEMBL23956106 | 0.74 | HTR7 (0.49) | HTR7P2RX7TRPV1 | |
| SCHEMBL23927833 | 0.72 | ABL1 (0.49) | HTR7 | |
| SCHEMBL2094768 | 0.72 | SLC6A2 (0.48) | DRD4DRD2DRD3SLC6A2SLC6A4 | |
| SCHEMBL2091301 | 0.71 | KCNH2 (0.49) | DRD4DRD2DRD3SLC6A2SLC6A4 | |
| SCHEMBL2849035 | 0.71 | HTR7 (0.41) | DRD2DRD3SLC6A2SLC6A4HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9415047-B2 | Use of benzo five-membered nitrogen heterocyclic piperazine or piperidine derivatives | Liaoning Emmy Biological Pharmaceutical Co., Ltd. (CN) | 2016-08-16 | — | — | US | disclosed |
| US-20150297586-A1 | USE OF BENZO FIVE-MEMBERED NITROGEN HETEROCYCLIC PIPERAZINE OR PIPERIDINE DERIVATIVES | Liaoning Emmy Biological Pharmaceutical Co., Ltd. (CN) | 2015-10-22 | — | — | US | disclosed |
| EP-2924033-A1 | USE OF BENZO FIVE-MEMBERED NITROGEN HETEROCYCLIC PIPERAZINE OR PIPERIDINE DERIVATIVES | Liaoning Emmy Biological Pharmaceutical Co., Ltd (CN) | 2015-09-30 | — | — | EP | disclosed |
| WO-2014079155-A1 | USE OF BENZO FIVE-MEMBERED NITROGEN HETEROCYCLIC PIPERAZINE OR PIPERIDINE DERIVATIVES | 辽宁贝雷生物制药有限公司 (CN) | 2014-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150297586-A1 | USE OF BENZO FIVE-MEMBERED NITROGEN HETEROCYCLIC PIPERAZINE OR PIPERIDINE DERIVATIVES | P2RX5, TBXA2R, CYP3A5 | DRD4 569/4885DRD2 445/4885DRD3 684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.